TRPV4 and atherosclerosis: These in vivo results demonstrate that TRPV4 hyperactivation exacerbates atherosclerosis by promoting inflammation and NLRP3 activation, whereas its inhibition confers strong protection, establishing TRPV4 as a key mechanistic target for treatment.